Literature DB >> 14992427

Transforming growth factor-beta (TGF-beta) protein levels are not elevated in the blood or bile of patients with primary sclerosing cholangitis: a pilot study.

J K Watt1, K Hawkins, M Zhang, J Lipschitz, G Sandha, Y Gong, J Uhanova, G Y Minuk.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disorder of unknown etiology characterized by progressive fibrosis and stricturing of the biliary tract. Transforming growth factor-beta (TGF-beta) is a family of cytokines produced by biliary tract epithelial cells that promote fibrinogenesis. Our objective was to determine whether TGF-beta levels are increased in the blood and/or bile of PSC patients compared to patients with other causes of obstructed biliary tracts (controls). Serum and bile TGF-beta levels were documented by enzyme-linked immunoassay in 10 adult PSC and 10 control patients obtained at the time of endoscopic retrograde cholangiography. Serum and bile TGF-beta levels were similar in the two groups (PSC versus control sera, 33.4 +/- 4.3 versus 27.5 +/- 7.7 ng/ml, and bile, 367 +/- 275 versus 457 +/- 247 ng/mg, respectively). Serum and bile TGF-beta levels are not increased in patients with PSC. Hence, the results of this pilot study do not support the hypotheses that PSC is caused by dysregulated TGF-beta expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14992427     DOI: 10.1023/b:ddas.0000011594.94294.12

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  7 in total

Review 1.  Primary sclerosing cholangitis.

Authors:  P Angulo; K D Lindor
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

Review 2.  Transforming growth factor beta and the liver.

Authors:  D M Bissell; D Roulot; J George
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

3.  Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment.

Authors:  G K Johnson; J E Geenen; R P Venu; M J Schmalz; W J Hogan
Journal:  Gastrointest Endosc       Date:  1991 Jan-Feb       Impact factor: 9.427

4.  Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders.

Authors:  W C Su; S C Shiesh; H S Liu; C Y Chen; N H Chow; X Z Lin
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

5.  Accumulation of macrophages in primary sclerosing cholangitis.

Authors:  R G Cameron; L M Blendis; M G Neuman
Journal:  Clin Biochem       Date:  2001-05       Impact factor: 3.281

Review 6.  Primary sclerosing cholangitis.

Authors:  Y M Lee; M M Kaplan
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

7.  Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis.

Authors:  N Sedlaczek; J D Jia; M Bauer; H Herbst; M Ruehl; E G Hahn; D Schuppan
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

  7 in total
  3 in total

1.  Application of multiplex arrays for cytokine and chemokine profiling of bile.

Authors:  Troy J Kemp; Felipe A Castro; Yu-Tang Gao; Allan Hildesheim; Leticia Nogueira; Bing-Sheng Wang; Lu Sun; Gloriana Shelton; Ruth M Pfeiffer; Ann W Hsing; Ligia A Pinto; Jill Koshiol
Journal:  Cytokine       Date:  2015-03-02       Impact factor: 3.861

2.  Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases.

Authors:  Masanori Koyabu; Kazushige Uchida; Hideaki Miyoshi; Yutaku Sakaguchi; Toshiro Fukui; Hiroki Ikeda; Makoto Takaoka; Junko Hirohara; Akiyoshi Nishio; Yoshiko Uemura; Shinji Uemoto; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2010-01-20       Impact factor: 7.527

3.  The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-β1 biliary secretion in mice.

Authors:  Nan Wu; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Julie Venter; Holly Standeford; Paolo Onori; Marco Marzioni; Domenico Alvaro; Antonio Franchitto; Eugenio Gaudio; Shannon Glaser; Gianfranco Alpini
Journal:  Hepatology       Date:  2016-06-11       Impact factor: 17.425

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.